611168-84-4Relevant articles and documents
Structure-Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796)
Regan, John,Capolino, Alison,Cirillo, Pier F.,Gilmore, Thomas,Graham, Anne G.,Hickey, Eugene,Kroe, Rachel R.,Madwed, Jeffrey,Moriak, Monica,Nelson, Richard,Pargellis, Christopher A.,Swinamer, Alan,Torcellini, Carol,Tsang, Michele,Moss, Neil
, p. 4676 - 4686 (2003)
We report on the structure-activity relationships (SAR) of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796), an inhibitor of p38α MAP kinase which has advanced into human clinical trials for the treatment of autoimmune diseases. Thermal denaturation was used to establish molecular binding affinities for this class of p38α inhibitors. The tert-butyl group remains a critical binding element by occupying a lipophilic domain in the kinase which is exposed upon rearrangement of the activation loop. An aromatic ring attached to N-2 of the pyrazole nucleus provides important π-CH 2 interactions with the kinase. The role of groups attached through an ethoxy group to the 4-position of the naphthalene and directed into the ATP-binding domain is elucidated. Pharmacophores with good hydrogen bonding potential, such as morpholine, pyridine, and imidazole, shift the melting temperature of p38α by 16-17 °C translating into Kd values of 50-100 pM. Finally, we describe several compounds that potently inhibit TNF-α production when dosed orally in mice.
